Loading
Loading…
Loading…
Ref. No.
Eligibility, documents, scope and key termsEligibility, required documents, scope of work and key terms of this tender, in one click.
Tender Value
Refer Docs
EMD Value
Exempted
Closing Date
11 Oct 2025, 10:00 amClosed
Eligibility, documents, scope and key termsEligibility, required documents, scope of work and key terms of this tender, in one click.
Suprabubic catheter 14 fr
Suprabubic catheter 16 fr
Inj Lignocaine 2 percnt 30 mlfor IV use
Tab Quetiapine 50 mg
Serum Anti Human globulin
Sulphamethoxazole 400 mg and Trimethoprim 80 mg
Clozapine 100 mg tab
Paroxetine CR 15 point 5 mg
8420971
GEM/2025/B/6744658
Two Packet Bid
Suprabubic catheter 14 fr
30 days
Hyderabad
Item wise evaluation
BOQ
8 documents required · 8 mandatory
3 yrs
₹31
₹1 L
50%
Exempted
11 Oct 2025
1 Oct 2025
11 Oct 2025
Suprabubic catheter 14 fr
Suprabubic catheter 16 fr
Inj Lignocaine 2 percnt 30 mlfor IV use
Tab Quetiapine 50 mg
Serum Anti Human globulin
Sulphamethoxazole 400 mg and Trimethoprim 80 mg
Clozapine 100 mg tab
Paroxetine CR 15 point 5 mg
Suprabubic cathether 14 fr
Suprabubic cathether 16 fr
Inj Lignocaine 2 percent 30 ml xylocard for IV use
Quetiapine 50 mg Tab
Serum Anti Human globulin
Sulphamethoxazole 400 mg and Trimethoprim 80 mg Tab Septran or Suristol
Clozapine 100 mg Tab
Paroxetine CR 12.5 mg
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_8420971.pdf
GEM_BID
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
document_62_2025-09-30-17-26-52_264bf89a7679ec91e11419d2a069a4e2.pdf
BOQ
bulk_gar_sample_file_26_2025-09-30-17-26-52_aea1c2bc419db8df3c2e407abdfd360f.csv.pdf
BOQ
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .